Helping You Build Wealth With Honest Research
Since 1996. Read On...

The Best Asset Allocation for Your Equity Portfolio

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Two Years of Market Correction
Is This Your Buying Window?

See Where the Opportunities are Emerging for the Next 3-5 Years


Grab the Opportunity

**Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.

AD

Market Crash: 5 High-ROE, Low-Debt Midcap Stocks Trading Below Their Own History

Oct 26, 2026

Market Crash: 5 High-ROE, Low-Debt Midcap Stocks Trading Below Their Own HistoryImage source: iQoncept/www.istockphoto.com

Midcaps are large enough to have established businesses, but still have room to expand into new markets, add capacity and improve their earnings profile.

This creates an opportunity to identify companies where the growth story is still developing.

In the current market environment however, stocks across the board have fallen.

And many good midcap companies are trading at attractive valuations.

But from the entire segment of 150 midcap companies, how to choose?

We put all of them through a rigorous filter. We selected only those midcaps which have an ROE and ROCE of at least 25%, a debt to equity ratio below 1, receivable days below 90, a dividend in the latest year, three straight years of sales and profit growth, and a PE below its 5-year average.

Here are 5 fundamentally strong midcap stocks to watch out.

#1 Abbott India

First on the list is Abbott India.

One of the top pharma companies in India, Abbott India is a division of Abbott Laboratories. It has a significant presence in pharmaceuticals, medical devices, nutritional products, and diagnostics.

Abbott was founded in 1910 and offers a wide range of products to meet different healthcare requirements throughout India.

The company sells branded pharmaceuticals in India and is 74.99% owned by its promoter.

It holds leadership in chronic and acute care segments, with 16 brands ranked #1 or #2 in their respective markets. 8 brands sit in the Top 100 of the Indian Pharmaceutical Market (IPM), and 10 brands are in the Top 300.

It has the best return ratios of the five names on the list, with an ROE of 34.4% and ROCE of 44.8%, on borrowings of just Rs 1.7 bn against reserves of Rs 47.5 bn.

Particulars (in Rs crore) FY23 FY24 FY25 FY26
Sales 5,349 5,849 6,409 6,929
Sales growth NA 9.30% 9.60% 8.10%
Net profit 949 1,201 1,414 1,552
Profit growth NA 26.60% 17.70% 9.80%
Dividend payout 73% 73% 71% 90%
Debtor days 22 20 22 19
Data Source: Equitymaster, Screener

In the most recent Q1 FY27, its revenue rose just 4.3% to Rs 18.1 bn, but EBITDA rose 17.3% to Rs 5.2 bn and the margin widened to 28.8% from 25.6%. Net profit was Rs 4.3 bn, up 17.1%.

The company has partnered with Novo Nordisk India to launch Extensior, broadening access to Semaglutide for advanced diabetes management.

The product targets type 2 diabetes management, offering HbA1c reduction, weight-loss benefits, and cardiovascular/kidney risk reduction.

Going forward, the company's focus is on therapy shaping to accelerate growth of leading brands through insight-led market strategies.

It is also focusing on beyond-the-pill patient support via education, counselling, and adherence programs, including women's health initiatives such as menopause-related support, with plans to scale through industry and startup collaboration.

For more details, check out its financial factsheet.

Want To Read The Full Article?

Enter your email to continue reading on Equitymaster.

Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster covering exciting investing ideas and opportunities in India.

Equitymaster requests your view! Post a comment on "Market Crash: 5 High-ROE, Low-Debt Midcap Stocks Trading Below Their Own History". Click here!